PipelineReview.com7h
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination ...
PipelineReview.com7h
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
NEWTOWN SQUARE, PA, USA and SHANGHAI, China I1, 2025 I ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company ...
PipelineReview.com7h
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior ...
PipelineReview.com7h
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
SAN DIEGO, CA; USA I January 21, 2025 I Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company ...
PipelineReview.com6h
Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 2025
BOSTON, MA, USA I1, 2025 I Antennova, a clinical-stage biotech company focused on oncology today announced the presentation of latest data from ...
PipelineReview.com7h
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
U.S. FDA issues clinical hold on EBVALLO™ (tabelecleucel) and ATA3219 studies linked to EBVALLO Complete Response Letter (CRL) ...
PipelineReview.com1d
Kelun-Biotech’s anti-PD-L1 (tagitanlimab) receives NMPA approval for marketing
CHENGDU, China I January 20, 2025 I Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) has received marketing authorization in China from ...
PipelineReview.com1d
New drug application for core product trastuzumab botidotin accepted by the National Medical Products Administration
CHENGDU, China I January 07, 2025 I The board (the “Board”) of directors (“Directors”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) is ...
PipelineReview.com1d
YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia
SHANGHAI, China I January 20, 2025 I YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the ...
PipelineReview.com2d
Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama
PLANEGG-MARTINSRIED, Germany I, 2025 I Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its licensing partner Klinge Biopharma GmbH ...
PipelineReview.com1d
Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe
SHANGHAI, China I, 2025 I Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...
PipelineReview.com1d
InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02
BEIJING, China I, 2025 I InnoCare Pharma (HKEX: 09969; SSE: 688428) and KeyMed Biosciences (HKEX: 02162) today announced that the two companies, ...